Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring System LR-MDS and RBC transfusion–dependent anemia a...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Oncol
Huvudupphovsmän: Garcia-Manero, Guillermo, Santini, Valeria, Almeida, Antonio, Platzbecker, Uwe, Jonasova, Anna, Silverman, Lewis R., Falantes, Jose, Reda, Gianluigi, Buccisano, Francesco, Fenaux, Pierre, Buckstein, Rena, Diez Campelo, Maria, Larsen, Stephen, Valcarcel, David, Vyas, Paresh, Giai, Valentina, Olíva, Esther Natalie, Shortt, Jake, Niederwieser, Dietger, Mittelman, Moshe, Fianchi, Luana, La Torre, Ignazia, Zhong, Jianhua, Laille, Eric, Lopes de Menezes, Daniel, Skikne, Barry, Beach, C. L., Giagounidis, Aristoteles
Materialtyp: Artigo
Språk:Inglês
Publicerad: Wolters Kluwer Health 2021
Ämnen:
ORIGINAL REPORTS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8099416/
https://ncbi.nlm.nih.gov/pubmed/33764805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02619
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk